The USFDA issued a second approvable letter for bazedoxifene, an estrogen receptor modulator being developed by Wyeth to prevent postmenopausal osteoporosis.
In its letter, the FDA identified several remaining questions regarding issues that had been previously identified during the review process and that were not fully resolved by Wyeth's complete response to the first approvable letter.
In its letter, the FDA identified several remaining questions regarding issues that had been previously identified during the review process and that were not fully resolved by Wyeth's complete response to the first approvable letter.
No comments:
Post a Comment